Cargando…

The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery

PURPOSE: The fibrinogen/albumin ratio (FAR) is increasingly considered as a potential biomarker for predicting prognosis in various malignant tumors, whereas the value of the FAR in predicting the recurrence-free survival (RFS) in patients with combined hepatocellular cholangiocarcinoma (cHCC-CCA) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jiake, Li, Shaochun, Feng, Ye, Zhang, Jie, Peng, Youduo, Wang, Xiaohong, Wang, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143788/
https://www.ncbi.nlm.nih.gov/pubmed/35637941
http://dx.doi.org/10.2147/CMAR.S361462
_version_ 1784715891685982208
author Xu, Jiake
Li, Shaochun
Feng, Ye
Zhang, Jie
Peng, Youduo
Wang, Xiaohong
Wang, Hongwei
author_facet Xu, Jiake
Li, Shaochun
Feng, Ye
Zhang, Jie
Peng, Youduo
Wang, Xiaohong
Wang, Hongwei
author_sort Xu, Jiake
collection PubMed
description PURPOSE: The fibrinogen/albumin ratio (FAR) is increasingly considered as a potential biomarker for predicting prognosis in various malignant tumors, whereas the value of the FAR in predicting the recurrence-free survival (RFS) in patients with combined hepatocellular cholangiocarcinoma (cHCC-CCA) after surgery has not been studied. PATIENTS AND METHODS: A total of 104 patients with surgical-pathologically proved cHCC-CCA were retrospectively analyzed. The best cut-off value of the FAR was calculated via receiver operating characteristic (ROC) curve analysis, and the cohort was then divided into two groups as high-FAR (H-FAR) group and low-FAR (L-FAR) group. The correlation between the preoperative FAR and clinicopathological characteristics was analyzed. Uni- and multi-variable analyses for RFS were evaluated using a Cox proportional hazards model to verify the predictive value of FAR on the RFS of cHCC-CCA. Additionally, a novel clinical nomogram based on FAR was developed to preoperatively predict the RFS of HCC-CCA. The C-index and calibration were conducted to evaluate the performance of the developed nomogram. RESULTS: According to the cut-off value of the FAR, the patients were grouped into the H-FARI (>0.075) and L-FARI (≤0.075) groups. FAR was significantly correlated with several clinical-pathological features, including age, cirrhosis, AFP, CA19-9, BCLC staging, NLR, and PLR. In the multi-variate analysis, FAR, cirrhosis and tumor size were independent prognostic predictors for poor RFS in cHCC-CCA patients after surgery. Moreover, the clinical nomogram based on FAR was constructed, showing well-predictive accuracy. CONCLUSION: The preoperative FAR is a convenient and feasible serum biomarker for predicting the RFS of cHCC-CCA after surgery. Such developed FAR-based nomogram integrating tumor size and cirrhosis could be served as a feasible and convenient tool to assist the decision-making of clinical strategy.
format Online
Article
Text
id pubmed-9143788
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91437882022-05-29 The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery Xu, Jiake Li, Shaochun Feng, Ye Zhang, Jie Peng, Youduo Wang, Xiaohong Wang, Hongwei Cancer Manag Res Original Research PURPOSE: The fibrinogen/albumin ratio (FAR) is increasingly considered as a potential biomarker for predicting prognosis in various malignant tumors, whereas the value of the FAR in predicting the recurrence-free survival (RFS) in patients with combined hepatocellular cholangiocarcinoma (cHCC-CCA) after surgery has not been studied. PATIENTS AND METHODS: A total of 104 patients with surgical-pathologically proved cHCC-CCA were retrospectively analyzed. The best cut-off value of the FAR was calculated via receiver operating characteristic (ROC) curve analysis, and the cohort was then divided into two groups as high-FAR (H-FAR) group and low-FAR (L-FAR) group. The correlation between the preoperative FAR and clinicopathological characteristics was analyzed. Uni- and multi-variable analyses for RFS were evaluated using a Cox proportional hazards model to verify the predictive value of FAR on the RFS of cHCC-CCA. Additionally, a novel clinical nomogram based on FAR was developed to preoperatively predict the RFS of HCC-CCA. The C-index and calibration were conducted to evaluate the performance of the developed nomogram. RESULTS: According to the cut-off value of the FAR, the patients were grouped into the H-FARI (>0.075) and L-FARI (≤0.075) groups. FAR was significantly correlated with several clinical-pathological features, including age, cirrhosis, AFP, CA19-9, BCLC staging, NLR, and PLR. In the multi-variate analysis, FAR, cirrhosis and tumor size were independent prognostic predictors for poor RFS in cHCC-CCA patients after surgery. Moreover, the clinical nomogram based on FAR was constructed, showing well-predictive accuracy. CONCLUSION: The preoperative FAR is a convenient and feasible serum biomarker for predicting the RFS of cHCC-CCA after surgery. Such developed FAR-based nomogram integrating tumor size and cirrhosis could be served as a feasible and convenient tool to assist the decision-making of clinical strategy. Dove 2022-05-23 /pmc/articles/PMC9143788/ /pubmed/35637941 http://dx.doi.org/10.2147/CMAR.S361462 Text en © 2022 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xu, Jiake
Li, Shaochun
Feng, Ye
Zhang, Jie
Peng, Youduo
Wang, Xiaohong
Wang, Hongwei
The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery
title The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery
title_full The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery
title_fullStr The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery
title_full_unstemmed The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery
title_short The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery
title_sort fibrinogen/albumin ratio index as an independent prognostic biomarker for patients with combined hepatocellular cholangiocarcinoma after surgery
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143788/
https://www.ncbi.nlm.nih.gov/pubmed/35637941
http://dx.doi.org/10.2147/CMAR.S361462
work_keys_str_mv AT xujiake thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT lishaochun thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT fengye thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT zhangjie thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT pengyouduo thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT wangxiaohong thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT wanghongwei thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT xujiake fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT lishaochun fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT fengye fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT zhangjie fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT pengyouduo fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT wangxiaohong fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery
AT wanghongwei fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery